Biotech Values

[DewDiligence]

teva is up because marth did a good job imo explaining how copaxone won't be cannabalized to a significant degree by oral agents (as well as gave high expectations for their own oral agent)

The more consequential reason, aside from the price increase on Copaxone, is that Marth reiterated Teva’s aggressive sales and EPS guidance for 2015 shown in #msg-56956538.

Marth and other Teva executives can reiterate these forecasts as often as they like, but Teva won’t be able to achieve these numbers if generic Copaxone reaches the US market.